Presentation Information
[O15-05]Long-term safety and tolerability of delandistrogene moxeparvovec in DMD: phase 1 to phase 3 clinical trials
○Keiko Ishigaki1, Crystal Proud2, Craig M. McDonald3, Eugenio M. Mercuri4, Francesco Muntoni5, Craig M. Zaidman6, Sachi Dharia7, Stefanie Mason7, Jianfeng Meng7, Alexander P. Murphy8, Emanuel Palatinsky7, Carol Reid8, Christoph Wandel9, Jerry R. Mendell7 (1.Tokyo Women's Medical University, School of Medicine, Department of Pediatrics, Tokyo, Japan, 2.Children's Hospital of The King's Daughters, Norfolk, VA, USA, 3.UC Davis, Davis, CA, USA, 4.Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS, Rome, Italy, 5.The Dubowitz Neuromuscular Centre, Great Ormond Street Institute of Child Health University College London, London, UK, 6.Washington University in Saint Louis, Saint Louis, MO, USA, 7.Sarepta Therapeutics, Inc., Cambridge, MA, USA, 8.Roche Products Ltd, Welwyn Garden City, UK, 9.F. Hoffmann-La Roche Ltd, Basel, Switzerland)